FGFR Inhibition Overcomes Resistance to EGFR-targeted Therapy in Epithelial-like Cutaneous Carcinoma.
Adrià Bernat-PegueraJuan Navarro-VenturaLaura Lorenzo-SanzVictoria da Silva-DizMattia BosioLuis PalomeroRosa M PeninDiana Pérez SidelnikovaJosep Oriol BermejoMiren TabernaNoelia VilariñoJosep M PiulatsRicard MesiaJoan Maria ViñalsEva González-SuárezSalvador CapellaAlberto VillanuevaFrancesc ViñalsPurificación MuñozPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
EGFR-targeted therapy may be appropriate for treating many epithelial-like cSCCs without PIK3CA-activating mutations. Combined EGFR- and FGFR-targeted therapy may be used to treat cSCCs that show intrinsic or acquired resistance to EGFR inhibitors.